| ABIVAX SA EO -,01 |
| Frankreich |
| Gesundheit |
| FR0012333284 / A14UQC |
| 2X1 (Frankfurt) |
| FRA:2X1, ETR:2X1, 2X1:GR |
| - |
| https://www.abivax.com/ |
|
Abivax SA is a France-based clinical-stage biotechnology company dedicated to developing innovative therapeutics that modulate the immune response in patients with chronic inflammatory diseases by harnessing the body's natural regulatory mechanisms, ..
>Volltext.. |
| 9172.13 Mio. EUR |
| 8714.83 Mio. EUR |
| - |
| -256.93 Mio. EUR |
| -329.75 Mio. EUR |
| -4.49 EUR |
| 33.96 Mio. EUR |
| 473.91 Mio. EUR |
| - |
| 7.9 |
| - |
| -124.85% |
| - |
| - |
| - |
| - |
| ABIVAX |
| 27.05.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|